SynthesisInternational urology and nephrology2020
Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis.
Synthesis in International urology and nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Pooled it
- Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.World journal of urology · 2024Trial
- Comparative efficacy and adverse effects of β3-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis.European journal of clinical pharmacology · 2025Article
- Reply to the comment on "Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meat-analysis".International urology and nephrology · 2021Article
- Letter to the editor.International urology and nephrology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe efficacy and safety of vibegron, which is a novel β3-adrenoceptor agonist, need to be systematically evaluated in the treatment of overactive bladder (OAB) patients. This study aimed to assess, using meta-analytic methods, the efficacy and safety of vibegron for OAB compared with placebo or antimuscarinics, considering all available data from comparative studies.
methodsA systematic search was performed on MEDLINE, Web of Science, and Cochrane Central Register of Controlled Trials database to identify studies from their date of inception before 15 March 2020. Meta-analysis was performed based on eligible studies.
resultsSix studies derived from four clinical trials with 4314 randomized patients were finally included in our analysis. We found that vibegron 50 mg and 100 mg were both significantly more efficacious than placebo for all efficacy outcomes. Furthermore, no significant differences were found between vibegron 50 mg or 100 mg and placebo for all the AEs assessed. In addition, the efficacy between vibegron 50 mg or 100 mg and antimuscarinics were comparable except for voided volume. Moreover, vibegron was associated with a decreased risk of dry mouth and an increased risk of nasopharyngitis versus antimuscarinics. Our study also demonstrated that the vibegron 50 mg and 100 mg were equally effective and safe across all the efficacy and AEs' outcomes.
conclusionsVibegron is effective and safe for treating patients with OAB. Based on the current evidence, we recommended that the initial use of vibegron 50 mg was the optimal algorithm in the pharmacologic management of OAB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.